Adoptive T-cell therapy is the administration of tumor cytotoxic T-cells derived from either patient himself or donors, which were induced or genetically engineered and expanded, and then injected into patients. Several strategies for adoptive T-cell therapy have been developed since last 30 years. From lymphokine-activated killer cells, tumor-infiltrating lymphocytes, cytokine-induced killer cells, to gene-modified T-cells and tumor associated antigen (TAA)-specific cytotoxic T-cells, the adoptive T-cell therapy has been moving forward to more precise tumor targeting and more effective in elimination of cancer cells. This article reviewed the advances of therapeutic approaches of adoptive T-cell therapy for cancer patients.

OBJECTIVETo explore breeding method and breed new varieties of Erigeron breviscapus.

METHODSuperior individual were selected from natural outcrossing population of E. breviscapus, lines and strains were established and selected and compared.

RESULTThe scutellarin contents of two E. breviscapus strains of 2003-15 and 2003-6 through line breeding were 3.21% and 3.01%, respectively, and increased 15.77% and 23.46% comparing with the control strain (QS-1), respectively, the yield increased 20.37% and 17.59%, scutellarin yield per hectare enhanced 39.31% and 44.82%.

CONCLUSIONNew varieties of E. breviscapus can be bred through lines breeding.

Breeding ; methods ; Erigeron ; growth & development